<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01627106</url>
  </required_header>
  <id_info>
    <org_study_id>6621-055</org_study_id>
    <nct_id>NCT01627106</nct_id>
  </id_info>
  <brief_title>A Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation (AF) (MK-6621-055)</brief_title>
  <official_title>A Multicentered, Randomized, Open-Label, Pragmatic Use Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiome Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiome Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare vernakalant therapy to amiodarone therapy in the acute management of
      recent onset atrial fibrillation.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants discharged from the emergency room (ER) to home, home-equivalent, or long-term care facility (LTCF) within 12 hours from randomization</measure>
    <time_frame>Up to 12 hours from randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants admitted to hospital directly from the ER after randomization</measure>
    <time_frame>Day 1 (time of ramdomization)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Vernakalant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Amiodarone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vernakalant</intervention_name>
    <description>Initial intravenous (IV) dose of 3 mg/kg (up to a maximum of 339 mg) over 10 minutes, followed by a 15 minute observation period and, if conversion to sinus rhythm does not occur within 15 minutes of the initial infusion, a second 10 minute infusion of vernakalant at a dose of 2 mg/kg (up to a maximum of 226 mg) will be administered.</description>
    <arm_group_label>Vernakalant</arm_group_label>
    <other_name>Brinavess</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone</intervention_name>
    <description>Administered IV as per product label</description>
    <arm_group_label>Amiodarone</arm_group_label>
    <other_name>Pacerone</other_name>
    <other_name>Cordarone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic AF (duration of current episode is â‰¤7 days), which is hemodynamically
             stable, and participant has no other condition at the time of screening that may
             result in acute hospitalization

          -  If female and of reproductive potential, the patient agrees to remain abstinent or use
             2 acceptable methods of birth control from time of screening until 30-day follow-up.

          -  Weigh at least 45 kg

          -  Receiving adequate anticoagulant therapy

        Exclusion Criteria:

          -  Hypersensitivity to the vernakalant or amiodarone or to citric acid, sodium chloride,
             sodium hydroxide, or iodine

          -  Severe aortic stenosis

          -  Systolic blood pressure &lt;100 mmHg

          -  New York Heart Association (NYHA) Class III or IV heart failure

          -  Severe bradycardia, sinus node dysfunction, or second and third degree heart block in
             the absence of a pacemaker

          -  Use of IV rhythm control anti-arrhythmics (Class I and III) within 4 hours of study
             drug administration

          -  Acute coronary syndrome (including myocardial infarction) within previous 30 days

          -  History of thyroid dysfunction

          -  Severe acute respiratory failure or cardiovascular collapse

          -  Participating in another drug study or has received an investigational drug within 30
             days prior to enrollment

          -  Pregnant or breast-feeding, or expecting to conceive from time of screening until
             30-day follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2012</study_first_submitted>
  <study_first_submitted_qc>June 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2012</study_first_posted>
  <last_update_submitted>August 23, 2013</last_update_submitted>
  <last_update_submitted_qc>August 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

